All Jeanne Marrazzo articles
-
NewsNIH-sponsored trial of Lassa vaccine opens
A National Institutes of Health (NIH)-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants at the University of Maryland School of Medicine, Baltimore.
-
NewsTecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovrimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial.
-
NewsNIH-funded clinical trial will evaluate new dengue therapeutic
A clinical trial is testing an experimental treatment designed to help people suffering the effects of dengue. An investigational therapeutic will be administered to adult volunteers who have been exposed to a weakened strain that causes a mild form of the disease.
-
NewsAs prevention strategy for sexually transmitted infections rolls out, experts highlight both promise and knowledge gaps
Real-world evidence demonstrates that the postexposure strategy of doxy PEP is reducing the rate of syphilis and chlamydia, but has had little to no effect on gonorrhea and needs close monitoring for signals of antibiotic resistance.
-
NewsLong-acting injectable cabotegravir for HIV prevention is safe in pregnancy
Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study.
-
NewsIsolated viral load test may generate false positive results for people using long-acting PrEP
A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.
-
NewsExperimental NIH malaria monoclonal antibody protective in Malian children
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results of a mid-stage clinical trial.
-
NewsLong-acting HIV treatment benefits adults with barriers to daily pill taking and adolescents with suppressed HIV
Long-acting, injectable antiretroviral therapy (ART) suppressed HIV replication better than oral ART in people who had previously experienced challenges taking daily oral regimens and was found safe in adolescents with HIV viral suppression.
-
NewsChildren surpass a year of HIV remission after treatment pause
Four children have remained free of detectable HIV for more than one year after their antiretroviral therapy (ART) was paused to see if they could achieve HIV remission.